Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20